Literature DB >> 22016080

Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis.

Kevin M Watt1, Matthew M Massaro, Brian Smith, Michael Cohen-Wolkowiez, Daniel K Benjamin, Matthew M Laughon.   

Abstract

Treatment of Mycoplasma hominis meningitis in infants is limited by a lack of consensus regarding therapy and limited pharmacokinetic data for agents to which M. hominis is susceptible. We report the successful treatment of a premature infant suffering from M. hominis meningitis with doxycycline and moxifloxacin and provide a pharmacokinetic profile of moxifloxacin.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22016080      PMCID： PMC3358780          DOI： 10.1097/INF.0b013e31823980c3

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  9 in total

Review 1.  The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens.

Authors:  A MacGowan; C Rogers; K Bowker
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

2.  Toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals.

Authors:  M Machida; H Kusajima; H Aijima; A Maeda; R Ishida; H Uchida
Journal:  Toxicol Appl Pharmacol       Date:  1990-09-15       Impact factor: 4.219

3.  Seizures occurring in pediatric patients receiving continuous infusion of bupivacaine.

Authors:  R Agarwal; D P Gutlove; C H Lockhart
Journal:  Anesth Analg       Date:  1992-08       Impact factor: 5.108

4.  The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time.

Authors:  S Riegelman; P Collier
Journal:  J Pharmacokinet Biopharm       Date:  1980-10

5.  Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man.

Authors:  H Stass; D Kubitza
Journal:  J Antimicrob Chemother       Date:  1999-05       Impact factor: 5.790

6.  Bactericidal properties of moxifloxacin and post-antibiotic effect.

Authors:  F J Boswell; J M Andrews; R Wise; A Dalhoff
Journal:  J Antimicrob Chemother       Date:  1999-05       Impact factor: 5.790

7.  A case of Mycoplasma hominis meningo-encephalitis in a full-term infant: rapid recovery after start of treatment with ciprofloxacin.

Authors:  Katja C Wolthers; René F Kornelisse; Gert J J M Platenkamp; M Inge Schuurman-van der Lem; Cindy van der Schee; Nico G Hartwig; Cees M Verduin
Journal:  Eur J Pediatr       Date:  2003-05-10       Impact factor: 3.183

Review 8.  Mycoplasma hominis meningitis in a neonate: case report and review.

Authors:  Atsuko Hata; Yuiko Honda; Kaoru Asada; Yuko Sasaki; Tsuyoshi Kenri; Daisuke Hata
Journal:  J Infect       Date:  2008-09-14       Impact factor: 6.072

9.  In-vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years.

Authors:  R Krausse; S Schubert
Journal:  Clin Microbiol Infect       Date:  2010-11       Impact factor: 8.067
  9 in total
  10 in total

1.  Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.

Authors:  Stephanie Thee; Anthony J Garcia-Prats; Heather R Draper; Helen M McIlleron; Lubbe Wiesner; Sandra Castel; H Simon Schaaf; Anneke C Hesseling
Journal:  Clin Infect Dis       Date:  2014-10-30       Impact factor: 9.079

2.  White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens.

Authors: 
Journal:  Clin Infect Dis       Date:  2012-08-13       Impact factor: 9.079

3.  Mycoplasma hominis Meningitis in a Full-Term Neonate: Rapid Recovery without Specific Treatment.

Authors:  Yan-Fen Huang; Xiao-Ping Mu
Journal:  Indian J Pediatr       Date:  2016-04-25       Impact factor: 1.967

4.  Successful Whole Genome Sequencing-guided Treatment of Mycoplasma hominis Ventriculitis in a Preterm Infant.

Authors:  Felicia A Scaggs Huang; Joel Mortensen; Jesse Skoch; Heidi Andersen; Mary Allen Staat; Joshua K Schaffzin; David B Haslam
Journal:  Pediatr Infect Dis J       Date:  2019-07       Impact factor: 2.129

5.  Population Pharmacokinetics of Moxifloxacin in Children.

Authors:  Rachel G Greenberg; Cornelia B Landersdorfer; Nazario Rivera-Chaparro; Melissa Harward; Thomas Conrad; Aya Nakamura; Carl M Kirkpatrick; Kenan Gu; Varduhi Ghazaryhan; Blaire Osborn; Emmanuel B Walter
Journal:  Paediatr Drugs       Date:  2022-03-14       Impact factor: 3.022

6.  A Case Report of Mycoplasma hominis Subdural Empyema Following Decompressive Craniotomy, and a Review of Central Nervous System Mycoplasma hominis Infections.

Authors:  Assaf Potruch; Guy Rosenthal; Ayelet Michael-Gayego; Violeta Temper; Mohanad Abdelrahman; Oshrat Ayalon; Ran Nir-Paz; Yonatan Oster
Journal:  Front Med (Lausanne)       Date:  2022-02-24

7.  Therapeutic Drug Monitoring of Moxifloxacin to Guide Treatment of Mycoplasma hominis Meningitis in an Extremely Preterm Infant.

Authors:  Telford Yeung; Erin Chung; Jennifer Chen; Laura K Erdman; Mina Smiljkovic; Waison Wong; Asaph Rolnitsky; Shaun K Morris; Amr El Shahed; Rudaina Banihani; Ari Bitnun; Christopher Tomlinson
Journal:  J Pediatr Pharmacol Ther       Date:  2021-11-10

8.  Pediatric anthrax clinical management.

Authors:  John S Bradley; Georgina Peacock; Steven E Krug; William A Bower; Amanda C Cohn; Dana Meaney-Delman; Andrew T Pavia
Journal:  Pediatrics       Date:  2014-05       Impact factor: 7.124

Review 9.  Evaluation of evidence for pharmacokinetics-pharmacodynamics-based dose optimization of antimicrobials for treating Gram-negative infections in neonates.

Authors:  Nusrat Shafiq; Samir Malhotra; Vikas Gautam; Harpreet Kaur; Pravin Kumar; Sourabh Dutta; Pallab Ray; Nilima A Kshirsagar
Journal:  Indian J Med Res       Date:  2017-03       Impact factor: 2.375

10.  Mycoplasma hominis meningitis in an extremely preterm newborn: a case report.

Authors:  Najmus Sehr Ansari; Elizabeth Asztalos; Asaph Rolnitsky
Journal:  BMC Pediatr       Date:  2021-02-08       Impact factor: 2.125
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.